πŸ‡ΊπŸ‡Έ FDA
Patent

US 11505585

FcRn antagonists and methods of use

granted A61KA61K38/00A61K38/1709

Quick answer

US patent 11505585 (FcRn antagonists and methods of use) held by The Board of Regents of the University of Texas System expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61K38/1709, A61K45/06, A61P